Atossa Therapeutics Inc (NASDAQ: ATOS) closed at $6.01 yesterday, up 30.09% on heavy volume. There’s an impressive rally on the company’s stock at NASDAQ. It is, in fact, too close to its 52-week high of $6.35 per share. The YTD surge in ATOS is almost 568%.
Interestingly, the stock did take part in the previous hypergrowth rally initially when the year began. In yesterday’s sessions, the stock gained some power on popular subreddits, mainly WallStreetBets.
The traction is attributed to some big news from ATOS. The company announced that it should be releasing its final data on June 9 from the Phase 2 study of Endoxifen. The drug is being marketed as a potential therapeutic pre-surgical tool in patients who have breast cancer. This release will mark its final data release from the study. Investors seem particularly interested in this webinar and its effect on the share price movement, especially on June 9.